share_log

Genix Announces TSX-V Approval of Warrant Amendments

Genix Announces TSX-V Approval of Warrant Amendments

Genix 宣佈多倫多證券交易所批准認股權證修正案
newsfile ·  02/07 02:29

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that pursuant to its news release of January 18, 2024, the TSX Venture Exchange has approved the Company's application to amend both the exercise price and the warrant accelerator terms, in addition to extending the expiry dates of 3,354,945 previously issued and outstanding warrants (the "Warrants").

不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2024 年 2 月 6 日)- Genix 製藥公司 多倫多證券交易所股票代碼:GENX)(場外交易代碼:GENPF)(“GENIX” 或 “公司”)宣佈,根據其2024年1月18日的新聞稿,多倫多證券交易所風險交易所已經批准了公司修改行使價和認股權證加速器條款的申請,此外還延長了其到期日 3,354,945 先前發行和未兌現的認股權證(“認股權證”)。

The current exercise price of the Warrants will be reduced from $0.30 per warrant share to $0.15 per warrant share. In addition, all of the Warrants will be subject to an accelerator repricing from $0.50 per share to a new accelerator price of $0.25 per share.

認股權證的當前行使價將從每股認股權證0.30美元降至每股認股權證0.15美元。此外,所有認股權證都將按加速器重新定價,從每股0.50美元調整爲每股0.25美元的新加速器價格。

Warrant Extension Terms

認股權證延期條款

  • 2,101,612* warrants will be extended to July 24, 2025
  • 1,253,333* warrants will be extended to August 13, 2025
  • 2,101,612* 份認股權證將延長至 2025 年 7 月 24 日
  • 1,253,333* 認股權證將延長至 2025 年 8 月 13 日

* The total warrants have been corrected from the following press releases announced on June 22, 2020, July 17, 2020, August 6, 2022, July 20, 2022, July 28 2022.

* 認股權證總數已根據2020年6月22日、2020年7月17日、2022年8月6日、2022年7月20日、2022年7月28日公佈的以下新聞稿進行了更正。

The Company notes that previous press releases (July 20, 2022 and July 28, 2022) had, due to a clerical error, incorrectly noted the warrants for July at 2,136,612 and Aug at 1,218,333. The full number of warrants remains the same. The Company also notes that the private placement announced on June 22, 2020, July 17, 2020 and August 6, 2020 issued a total of 6,609,894 common shares.

該公司指出,先前的新聞稿(2022年7月20日和2022年7月28日) 由於筆誤,他錯誤地將7月份的認股權證記爲2,136,612份,8月份的認股權證爲1,218,333份。認股權證的全部數量保持不變。該公司還指出,於2020年6月22日、2020年7月17日和2020年8月6日宣佈的私募共發行了6,609,894股普通股。

Genix sincerely apologizes for any inconvenience caused by the inadvertent provision of incorrect warrant numbers. We regret any disruptions this may have caused and appreciate your understanding.

對於因無意中提供錯誤的認股權證號碼而造成的任何不便,Genix深表歉意。我們對由此可能造成的任何干擾深表歉意,並感謝您的理解。

About Genix

關於 Genix

Genix Pharmaceuticals Corporation is a novel and generic ophthalmic drugs company. The Company is focused on the research, development, manufacture, licensing and sales of novel and innovative healthcare products. In particular, these products include evidence-based, proprietary over-the-counter ("OTC") nutraceuticals, and other single molecule generic drugs that have been shown to deliver consistent and verifiable results in various therapeutic areas.

Genix製藥公司是一家新型的仿製眼科藥物公司。該公司專注於新穎和創新的醫療保健產品的研究、開發、製造、許可和銷售。特別是,這些產品包括基於證據的專有非處方(“OTC”)營養品,以及其他單分子仿製藥,這些藥物已被證明可以在各個治療領域提供一致和可驗證的結果。

On Behalf of the Board of Directors,

代表董事會,

Mr. Mahmoud Aziz, President, Director
Genix Pharmaceuticals Corporation

馬哈茂德·阿齊茲先生,總裁、董事
Genix 製藥公司

For more information regarding Genix Pharmaceuticals Corporation, please contact:

有關 Genix 製藥公司的更多信息,請聯繫:

Kevin Bottomley, Director
Tel: +1.604.609.6199
kbottomley@genixpharm.com

凱文·布托姆利,導演
電話:+1.604.609.6199
kbottomley@genixpharm.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward‐looking statements". Forward‐looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.

本公告中包含的聲明,包括有關我們的計劃、意圖和期望的聲明,本質上不是歷史性的,特此定義爲 “前瞻性陳述”。前瞻性陳述可以通過包括 “預期”、“相信”、“打算”、“估計”、“期望” 和類似表述在內的詞語來識別。公司提醒讀者,前瞻性陳述,包括但不限於與公司未來運營和業務前景相關的陳述,存在某些風險和不確定性,可能導致實際業績與前瞻性陳述中顯示的結果存在重大差異。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論